BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD

0
109

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential. On December 12, Bank of America raised the firm’s price target on Ocular Therapeutix to $21 from $18 and maintained a Buy rating on the shares. After hosting CEO Pravin Dugel to review upcoming corporate milestones, the firm highlighted the development strategy for AXPAXLI, supported by pivotal trials in both wet AMD and diabetic retinopathy. BofA remains optimistic about the drug’s unique competitive advantages and the possibility of a faster regulatory path.

On December 8, Ocular Therapeutix Inc. (NASDAQ:OCUL) announced a major acceleration of its regulatory strategy for AXPAXLI (OTX-TKI), which is an investigational treatment for wet age-related macular degeneration (wet AMD). The company now plans to submit an NDA shortly after receiving one-year data from its…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here